Author

Qingbiao Chen

Institutions: Guangdong Pharmaceutical University, Foshan Second People's Hospital

Observed institutions: Jinan University, Guangdong Pharmaceutical University, Foshan Second People's Hospital, Southern Medical University

ORCID: 0009-0006-5765-8841

Observed ORCID: 0009-0006-5765-8841

OpenAlex ID: A5081887821

Silencing HOXC13 exerts anti-prostate cancer effects by inducing DNA damage and activating cGAS/STING/IRF3 pathway

2023 · Maozhang Li, Guangwei Bai, et al. · Journal of Translational Medicine · 20

Effects of Dezocine and Sufentanil on Th1/Th2 Balance in Breast Cancer Patients Undergoing Surgery

2021 · Xudong Hu, Bing Luo, et al. · Drug Design Development and Therapy · 16

Dezocine Has the Potential to Regulate the Clinical and Biological Features of Tumors

2022 · Xudong Hu, Bing Luo, et al. · Drug Design Development and Therapy · 7

A THBS2+ cancer-associated fibroblast subpopulation orchestrates therapeutic resistance in castration-resistant prostate cancer

2026 · Qingbiao Chen, Zexi He, et al. · Scientific Reports

Works count: 4

Citation count: 43

H-index: 3

I10-index: 2